久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Inovio signs deal with Japan’s Kaneka for COVID-19 vaccine manufacturing

expresspharmaDecember 04, 2020

Tag: INOVIO , kaneka , COVID-19 Vaccine

Japan’s Kaneka Corp has entered into a deal to manufacture Inovio Pharmaceuticals’ COVID-19 vaccine candidate, informed the company.

It did not disclose the terms of the agreement with Kaneka Eurogentec, a unit of the Japanese chemical company.

Inovio has also signed manufacturing deals with medical device maker Thermo Fisher Scientific among others, to increase the supply of the vaccine, which entered a mid-stage study last month.

The Phase 3 of the mid-to-late stage study is under a partial hold by the US Food and Drug Administration as it seeks more information, including details on a delivery device used to inject genetic material into cells.

Previous:Solutions For Powder Properties in Pharmaceuticals: Visit Micromeritics and Freeman technology in CPhI China 2020

Next:Indian pharma: Driving excellence in quality and patient centricity

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service